Retatrutide vs Tirzepatide
Tirzepatide is FDA-approved and produced about 20% weight loss in trials. Retatrutide adds a third receptor (glucagon), produced about 24% in phase 2, and is not yet approved. Retatrutide showed more weight loss and faster early results; tirzepatide has far more safety data and is obtainable as a regulated product.
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Receptors | GLP-1 + GIP + glucagon (triple) | GLP-1 + GIP (dual) |
| FDA status | Investigational (phase 3) | Approved (Mounjaro, Zepbound) |
| Trial weight loss | ~24% at 48 weeks, 12 mg (phase 2) | ~21% at 72 weeks, 15 mg (SURMOUNT-1) |
| Trial dose range | 1–12 mg weekly | 2.5–15 mg weekly |
| Starting dose in trials | 2 mg | 2.5 mg |
| Dosing frequency | Weekly | Weekly |
| Effect on liver fat | Large reductions in phase 2 | Reductions shown |
| Heart rate | Larger increase (glucagon effect) | Modest increase |
| GI side effects | Common, dose-dependent | Common, dose-dependent |
| Long-term safety data | None yet | Multi-year |
| Availability | Research compounds only | Pharmacy, compounding, research compounds |
Mechanism difference
The glucagon component in retatrutide increases energy expenditure and mobilizes liver fat. That's the source of both the additional weight loss and the additional heart-rate increase. Tirzepatide relies on appetite suppression and improved insulin response without the glucagon effect.
Trial results in context
The two compounds have not been compared head-to-head. Retatrutide's 24% is from a 48-week phase 2 study where weight was still dropping at the end; tirzepatide's 21% is from a 72-week phase 3 study. Phase 3 retatrutide results (TRIUMPH program) will give the clearer comparison.
Practical differences
Tirzepatide can be obtained as a prescription product with known purity. Retatrutide cannot — every vial on the market is unregulated, and underdosed or mislabeled product is a real risk. For anyone buying research retatrutide, COA verification is not optional.
Frequently asked questions
Is retatrutide stronger than tirzepatide?
In separate trials, retatrutide produced more weight loss. No direct comparison has been published.
Is retatrutide approved?
No. It is in phase 3 trials.
Can you switch from tirzepatide to retatrutide?
There is no published protocol. Anecdotal reports describe restarting at the lowest retatrutide dose rather than matching the tirzepatide dose.
Which has fewer side effects?
Both have similar GI profiles. Retatrutide has a larger heart-rate increase.
Which one should I use?
If regulated product and safety data matter, tirzepatide. Retatrutide is a research compound with promising but incomplete data.
Verify a retatrutide or tirzepatide vendor's COA before you buy — scan it in PepIQ.
Use PepIQ to scan vials and access the verified peptide shop.
Open in App Store